tetano
Editor, Senior Moderator
Clin Chem Lab Med
. 2020 Jun 29;/j/cclm.ahead-of-print/cclm-2020-0727/cclm-2020-0727.xml.
doi: 10.1515/cclm-2020-0727. Online ahead of print.
Do Genetic Polymorphisms in Angiotensin Converting Enzyme 2 (ACE2) Gene Play a Role in Coronavirus Disease 2019 (COVID-19)?
Giuseppe Lippi[SUP] 1 [/SUP], Carl J Lavie[SUP] 2 [/SUP], Brandon M Henry[SUP] 3 [/SUP], Fabian Sanchis-Gomar[SUP] 4 5 [/SUP]
AffiliationsExpand
Abstract
Although some demographic, clinical and environmental factors have been associated with a higher risk of developing coronavirus disease 2019 (COVID-19) and progressing towards severe disease, altogether these variables do not completely account for the different clinical presentations observed in patients with comparable baseline risk, whereby some subjects may remain totally asymptomatic, whilst others develop a very aggressive illness. Some predisposing genetic backgrounds can hence potentially explain the broad inter-individual variation of disease susceptibility and/or severity. It has been now clearly established that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing COVID-19, infects the host cell through biding and being internalized with angiotensin converting enzyme 2 (ACE2), a surface protein expressed in a noticeable number of human cells, especially in those of upper and lower respiratory tracts, heart, kidney, testis, adipose tissue, gastrointestinal system and in lymphocytes. Accumulating evidence now suggests that genetic polymorphisms in the ACE2 gene may modulate intermolecular interactions with the spike protein of SARS-CoV-2 and/or contribute to pulmonary and systemic injury by fostering vasoconstriction, inflammation, oxidation and fibrosis. We hence argue that the development of genetic tests aimed at specifically identifying specific COVID-19-susceptible or -protective ACE2 variants in the general population may be a reasonable strategy for stratifying the risk of infection and/or unfavorable disease progression.
Keywords: COVID-19; angiotensin; enzyme; polymorphism; receptor.
. 2020 Jun 29;/j/cclm.ahead-of-print/cclm-2020-0727/cclm-2020-0727.xml.
doi: 10.1515/cclm-2020-0727. Online ahead of print.
Do Genetic Polymorphisms in Angiotensin Converting Enzyme 2 (ACE2) Gene Play a Role in Coronavirus Disease 2019 (COVID-19)?
Giuseppe Lippi[SUP] 1 [/SUP], Carl J Lavie[SUP] 2 [/SUP], Brandon M Henry[SUP] 3 [/SUP], Fabian Sanchis-Gomar[SUP] 4 5 [/SUP]
AffiliationsExpand
- PMID: 32598305
- DOI: 10.1515/cclm-2020-0727
Abstract
Although some demographic, clinical and environmental factors have been associated with a higher risk of developing coronavirus disease 2019 (COVID-19) and progressing towards severe disease, altogether these variables do not completely account for the different clinical presentations observed in patients with comparable baseline risk, whereby some subjects may remain totally asymptomatic, whilst others develop a very aggressive illness. Some predisposing genetic backgrounds can hence potentially explain the broad inter-individual variation of disease susceptibility and/or severity. It has been now clearly established that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing COVID-19, infects the host cell through biding and being internalized with angiotensin converting enzyme 2 (ACE2), a surface protein expressed in a noticeable number of human cells, especially in those of upper and lower respiratory tracts, heart, kidney, testis, adipose tissue, gastrointestinal system and in lymphocytes. Accumulating evidence now suggests that genetic polymorphisms in the ACE2 gene may modulate intermolecular interactions with the spike protein of SARS-CoV-2 and/or contribute to pulmonary and systemic injury by fostering vasoconstriction, inflammation, oxidation and fibrosis. We hence argue that the development of genetic tests aimed at specifically identifying specific COVID-19-susceptible or -protective ACE2 variants in the general population may be a reasonable strategy for stratifying the risk of infection and/or unfavorable disease progression.
Keywords: COVID-19; angiotensin; enzyme; polymorphism; receptor.